Renal denervation in China: momentum, insights, and evolution

Anchorperson: F. Mahfoud

Spokesperson: J. Li

Summary

This EuroPCR 2026 session highlights the rapidly evolving clinical experience of renal denervation (RDN) in China following regulatory approval, with a focus on real-world practice and programme development.

It reviews how structured, patient-centred hypertension pathways are being integrated with RDN, alongside practical strategies for managing complex renal anatomies such as multiple renal arteries. The discussion emphasises the importance of standardised procedural workflows, comprehensive imaging assessment, and device planning to optimise safety, consistency, and effectiveness. Shared decision-making is also explored as a key element in contemporary hypertension care, supporting better blood pressure control and improved long-term cardiovascular outcomes.

Learning Objectives

To learn how renal denervation is practiced in China after approval
To learn how to manage your renal denervation procedure based on China renal denervation practice
To learn how to manage hypertension patients with renal denervation based on China renal denervation practice

Speaker

J. Li

Welcome and session objectives